GlobalPost Examines Debate Surrounding PrEP
July 30, 2012
GlobalPost's "Global Pulse" blog examines questions surrounding the use of the antiretroviral Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among people at high risk, as studies released and panel discussions held last week at the XIX International AIDS Conference (AIDS 2012) "raised concerns about the drug's effect on the future of the AIDS fight." According to the blog, "Leaders in the fight against AIDS are trying to work through these issues and figure out the best way to make use of Truvada as prevention." The blog notes that the WHO last week "released a set of guidelines for how to use PrEP in demonstration projects" and quotes AVAC Director Mitchell Warren, AIDS Healthcare Foundation President Michael Weinstein, amfAR Vice President and Director of Public Policy Chris Collins, and Black AIDS Institute President and CEO Phill Wilson (Judem, 7/27).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)